GHRP-6

What it is

Six amino acids make up this synthetic hexapeptide, GHRP-6. Its history goes back to the 1980s, one of the earliest growth hormone secretagogues built, a class of compounds meant to push the body toward releasing more of its own growth hormone rather than deliver growth hormone from outside. The molecule works mainly through a receptor called GHS-R1a, the same one the hunger hormone ghrelin binds to, which is also why it is reported to strongly stimulate appetite.

Beyond its role in growth-hormone release, researchers have studied GHRP-6 for a second, separate property: activity at a receptor called CD36, found in heart tissue and elsewhere, that appears unrelated to growth hormone. Work in this area has looked at whether that receptor activity protects tissue during periods of reduced blood flow or drug-induced damage, an area of research described in the literature as cytoprotective, meaning cell-protecting.

How it is studied

GHRP-6 has been studied in human volunteers for its growth-hormone-releasing effect, often measuring hormone levels in blood after a single research amount was given. Its separate cardioprotective property has mostly been studied in rats given a heart-damaging cancer drug. Its combination with a separate growth factor, epidermal growth factor (EGF), has been tested in a large randomized clinical trial in people with acute ischemic stroke. It is frequently studied alongside a different family of growth-hormone-releasing compounds because the two types are reported to act through separate pathways that add together.

What studies report

• A review tracing decades of research on GHRP-6 and related peptides reports that they bind to two separate receptors, one of which turns on cell-survival signaling, reduces damaging reactive particles inside cells, and lowers inflammation, with protective effects described in heart, nerve, gut, and liver cells across various laboratory and animal studies. [berlanga-2017]
• In rats given a heart-damaging cancer drug called doxorubicin, giving GHRP-6 alongside it prevented the drop in heart pumping function and heart muscle loss that the drug otherwise caused, and also reduced damage to other organs, apparently by turning on cell-survival genes and antioxidant defenses. [berlanga-2024-dox]
• In a randomized trial of 188 people with acute ischemic stroke, adding EGF and GHRP-6 to standard care did not improve overall disability or survival at six months compared with standard care alone; however, the smaller group of patients with the most severe strokes who received the combination had less disability and a lower risk of death than similar patients on standard care alone. [hernandez-bernal-2026]

What is not known

How its appetite-stimulating effect and its tissue-protective effect relate to each other is not resolved by the published literature reviewed for this profile. The largest and most rigorous human trial of the EGF plus GHRP-6 pairing, run in people who had just had an acute ischemic stroke, missed its main goal of showing an overall disability benefit; only a subgroup of patients with the most severe strokes showed a clear benefit, so whether the combination helps stroke patients in general remains unresolved and would need to be confirmed in a trial designed around that more severe group.

Reported adverse findings

• In the phase III stroke trial, severe adverse events occurred in about a third of patients in both the treatment and standard-care groups, a difference the researchers said was not statistically significant, and none of the severe adverse events were judged to be caused by the treatment. [hernandez-bernal-2026]

Regulatory status

GHRP-6 has not received approval from the United States Food and Drug Administration or from any other national medicines regulator for human use. The World Anti-Doping Agency does not list it by name among banned substances, though the wider category of growth hormone secretagogues is barred in competitive sport.